Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Day One Biopharmaceuticals Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units, indicating that the company's pharmaceutical research is being reviewed in different specialized groups. The involvement of 2 distinct examiners means each case is being reviewed by a different person, allowing for independent assessment of the technical merits of each application.
MOU, LIYUAN is the busiest examiner for the company, with 1 pending office action. With 2 pending office actions and the distinct examiners, the workload is evenly divided, with the busiest examiner managing a portion of the cases. This distribution across 2 distinct art units and examiners requires the applicant to handle separate prosecution paths. The lack of concentration with a single examiner or art unit provides a level of diversification for the portfolio.
For a practitioner, the Biotechnology & Pharmaceuticals focus requires adapting to the specific requirements of the different art units. The 1 pending office action under the busiest examiner represents half of the active workload, making its outcome significant. The applicant must address the unique technical challenges and examiner styles present in each case. Coordinating these efforts is necessary to ensure that the company's broader pharmaceutical strategy remains consistent across the distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| JANOSKO, CHASITY PAIGE | 1 | 15.9% | +63.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17824237 | SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR | JANOSKO, CHASITY PAIGE | 74d overdue |
| 18332906 | ORAL LIQUID SUSPENSION OF PAN-RAF KINASE INHIBITOR | MOU, LIYUAN | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17824237 | SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR | JANOSKO, CHASITY PAIGE | 74d overdue |
| 18332906 | ORAL LIQUID SUSPENSION OF PAN-RAF KINASE INHIBITOR | MOU, LIYUAN | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18332906 | ORAL LIQUID SUSPENSION OF PAN-RAF KINASE INHIBITOR | MOU, LIYUAN | 1628 | §103§112 | Final Rejection | 31d overdue | Pending | Jun 12, 2023 |
| 17824237 | SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR | JANOSKO, CHASITY PAIGE | 1613 | §103 | Final Rejection | 74d overdue | Pending | May 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDay One Biopharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Liyuan Mou has the most, with 1 of Day One Biopharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
